香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公佈全部或任何 部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 二零二五年八月七日 中國山東省威海市 董事會會議通告 山東威高集團醫用高分子製品股份有限公司（「本公司」）董事會（「董事會」）謹此宣 佈，董事會會議將於二零二五年八月二十七日（星期三）舉行，藉以(其中包括)考慮及 批准本公司及其附屬公司截至二零二五年六月三十日止六個月之未經審核中期業績及 其發佈以及考慮派發中期股息（如有）。 承董事會命 山東威高集團醫用高分子製品股份有限公司 董事長 龍經 於本公佈刊發日期，董事會成員包括： * 僅供識別 龍 經先生 （執行董事） 叢日楠先生 （執行董事） 盧均強先生 （執行董事） 王道明先生 （執行董事） 燕 霞女士 （非執行董事） 陳 林先生 （非執行董事） 湯正鵬先生 （非執行董事） 李國輝先生 （獨立非執行董事） 孟 紅女士 （獨立非執行董事） 李 強先生 （獨立非執行董事） 孫 恆先生 （獨立非執行董事） ...

（原标题：瑞银：料内地医疗设备板块本季起复苏 首选威高股份(01066)） 智通财经APP获悉，瑞银发布研报称，预期次季及上半年内地医药器械股份的业绩将继续分化。展望下 半年，料设备企业的国内收入将自第三季起显著增长，因上半年恢复招标逐步转化为收入。体外诊断 (IVD)方面，虽然部分试剂价格或于第三季触底，但用量影响或要到今年末才会消退。耗材方面，各品 类分化的势态将延续至下半年，另外该行关注国家医疗保障局近期强调带量采购"反内卷"后续政策，可 能是中长期催化剂。海外业务方面，该行认为除非中美关税争端再起，各板块应可维持稳定增长。 该行最新较看好联影医疗(688271.SH)及威高股份(01066)，前者2025至27年收入有强劲增长潜力，估值 溢价合理，予目标价192元人民币，评级"买入"。后者今年全年10%至15%的收入增长指引虽然面临下 行风险，但其收入及盈利有所增长，股东回报持续改善，且估值合理，目标价8.2港元，亦予"买入"评 级。 ...

Core Viewpoint - UBS forecasts continued performance divergence among domestic medical device stocks in the second quarter and the first half of the year, with significant revenue growth expected for equipment companies starting in the third quarter as tender recovery translates into income [1] Group 1: Market Trends - Domestic revenue for equipment companies is anticipated to see significant growth from the third quarter due to the gradual conversion of tender recovery into income [1] - In vitro diagnostics (IVD) may see some reagent prices bottoming out in the third quarter, but the impact on usage may not dissipate until the end of the year [1] - The trend of differentiation among various categories of consumables is expected to continue into the second half of the year [1] Group 2: Policy and Regulatory Environment - The National Healthcare Security Administration's recent emphasis on "anti-involution" policies regarding volume-based procurement may serve as a medium to long-term catalyst for the industry [1] Group 3: International Business Outlook - The outlook for overseas business remains stable across various sectors unless the US-China tariff dispute resurfaces [1] Group 4: Company Recommendations - UBS is optimistic about United Imaging Healthcare (688271.SH), projecting strong revenue growth potential from 2025 to 2027, with a target price of 192 RMB and a "Buy" rating [1] - Wego Group (01066) is also rated "Buy," with a revenue growth guidance of 10% to 15% for the year, despite facing downside risks; the company is expected to see revenue and profit growth along with improving shareholder returns, with a target price of 8.2 HKD [1]

瑞银发表研究报告指，预期次季及上半年内地医药器械股份的业绩将继续分化。展望下半年，预计设备 企业的国内收入将自第三季起显著增长，因上半年恢复招标逐步转化为收入。 体外诊断(IVD)方面，虽 然部分试剂价格或于第三季触底，但用量影响或要到今年末才会消退。耗材方面，各品类分化的势态将 延续至下半年，另外该行关注国家医疗保障局近期强调带量采购反内卷后续政策，可能是中长期 催化 剂。海外业务方面，该行认为除非中美关税争端再起，各板块应可维持稳定增长。 该行最新较看好 联 影医疗及威高股份。联影医疗2025至27年收入有强劲增长潜力，估值溢价合理，予目标价192元，评 级"买入"。威高股份今年全年10%至15%的收入增长指引虽然面临下行风险，但其收入及盈利有所增 长，股东回报持续改善，且估值合理，目标价8.2港元，亦予"买入"评级。 ...

Core Insights - The article discusses the development and branding strategies of Weigao Group in the medical and healthcare industry, emphasizing their commitment to quality management and innovation Group 1: Brand and Quality Management - Weigao Group has been recognized with a nomination for the China Quality Award, establishing a diversified brand system centered around "WEGO" [1] - The company implements a quality philosophy termed "10000-1=0," which signifies that even a minor defect can lead to total failure, reinforcing the importance of quality as the brand's lifeline [2] - Weigao has established a comprehensive traceability quality control system from raw material procurement to finished products, aiming for "zero defects" in product reliability [2] Group 2: Innovation and Market Leadership - Innovation is a core driver for Weigao, which holds over 2100 patents and has established 15 national and provincial innovation platforms [3] - The company has successfully broken monopolies in key areas such as medical materials and devices, transitioning from import substitution to international leadership [3] - Collaborations with institutions like the Chinese Academy of Sciences have enabled Weigao to develop domestic alternatives to imported materials, fostering a new growth dynamic in the medical device sector [3] Group 3: Cultural Integration and Brand Identity - Weigao emphasizes the integration of internal culture and external values, promoting a core value system of "conscience, sincerity, and loyalty" [4] - The company's mission is deeply embedded in its brand culture, encouraging over 30,000 employees to embody and promote the brand's values [4] - This cultural drive transforms employee pride into a pursuit of product excellence, enhancing customer trust and societal expectations of the brand [4]

水泥(大部份已反映)：中国建材 医疗(大部份已反映)：三生制药、威高股份 保险(部份已反映)：中国平安、太保 猪肉(部份已反映)：牧原股份、温氏股份 太阳能供应链(轻微反映)：协鑫科技、通威股份、隆基绿能 餐饮外卖(轻微反映)：阿里巴巴 锂(轻微反映)：盐湖股份 化工(未反映)：华鲁恒升、恒力石化 汽车(未反映)：比亚迪、理想汽车、长城汽车 格隆汇8月5日｜瑞银发表报告，列出潜在受惠"反内卷"政策的板块和首选股名单，并关注相关板块股价 是否已反映相关因素。 ...

Group 1: Industry Overview - The main listed companies in the borosilicate glass industry include Shandong Pharmaceutical Glass, Linuo Pharmaceutical Packaging, Qibin Group, Weigao Group, and Zhengchuan Co., Ltd. [1] - The number of A-share listed companies in the borosilicate glass sector is relatively small, with key players being Shandong Pharmaceutical Glass, Linuo Pharmaceutical Packaging, Qibin Group, and Zhengchuan Co., Ltd. [1] Group 2: Financial Performance - In 2024, the projected revenue for Shandong Pharmaceutical Glass from borosilicate glass-related businesses is 51.30 billion yuan, Linuo Pharmaceutical Packaging is 10.81 billion yuan, and Qibin Group is 156.49 billion yuan [2]. - The revenue contribution of borosilicate glass-related businesses to total revenue is significant, with Shandong Pharmaceutical Glass at 51.38%, Linuo Pharmaceutical Packaging at 43.24%, and Zhengchuan Co., Ltd. at 52.85% [5]. Group 3: Production and Sales Metrics - In 2024, Shandong Pharmaceutical Glass and Zhengchuan Co., Ltd. have production and sales rates close to 100%, while Linuo Pharmaceutical Packaging's rate is below 90% [6]. - The gross profit margin for Shandong Pharmaceutical Glass is notably high, while Linuo Pharmaceutical Packaging and Zhengchuan Co., Ltd. have margins around 22%-23% [6]. Group 4: Business Layout and Strategy - The borosilicate glass industry is concentrated in the eastern coastal regions of China, particularly in Jiangsu Province [2]. - Leading companies like Shandong Pharmaceutical Glass and Linuo Pharmaceutical Packaging are expanding capacity and integrating the supply chain to accelerate domestic substitution in the borosilicate glass market [8]. Group 5: Future Plans - Shandong Pharmaceutical Glass aims to increase its production capacity to 5 billion units per year by 2025, with a target export ratio of 20%-25% [9]. - Linuo Pharmaceutical Packaging plans to achieve a production capacity of 63,000 tons per year by 2025, covering all specifications from 5ml to 500ml [9]. - Qibin Group is investing 780 million yuan to build two production lines for borosilicate glass, expected to be operational by 2025 with an annual capacity of 100,000 tons [9].

Group 1: Market Overview - The Hang Seng Index fell by 1.11%, down 284 points, closing at 25,383 points, while the Hang Seng Tech Index dropped by 1.69% [1] - The early trading volume in Hong Kong stocks reached 151 billion HKD [1] Group 2: Medical Sector - Medical device stocks rose in early trading, with the national drug procurement policy indicating a move away from internal competition, leading institutions to view this as a turning point for the industry [1] - Aikang Medical (01789) increased by 7.93%, and Weigao Group (01066) rose by 4.37% [1] - Yongsheng Medical (01612) saw a surge of over 27% following a profit warning, with sales orders increasing and expected mid-term net profit growth exceeding 50% year-on-year [2] - CRO concept stocks continued to rise, with Citigroup noting that the CXO sector is gaining market attention ahead of earnings season [2] - Kanglong Chemical (300759) (03759) rose by 8.4%, while Zhaoyan New Drug (603127) (06127) increased by 5.7%, and WuXi Biologics (02269) rose by 4.5% [2] Group 3: Consumer Sector - Nongfu Spring (09633) increased by over 3.56%, reaching a three-and-a-half-year high, with institutions expecting the company's first-half revenue growth to exceed market expectations [3] Group 4: Other Notable Stocks - Jihong Co., Ltd. (002803) (02603) rose by 16%, with two main business segments performing well, and expected first-half net profit growth of up to 65% [4] - China Merchants Port (01199) increased by over 4%, following reports that China Merchants Group plans to acquire assets from Cheung Kong Ports [5] - Guichuang Tongqiao (02190) rose by 2.6%, with expected mid-term net profit growth of 66.9%, as the company embraces procurement and actively expands overseas [6] Group 5: Lithium and Duty-Free Sector - News of supply disruptions in the lithium market led to Tianqi Lithium (002466) (09696) rising by 3.6% [7] - China Duty Free Group (601888) (01880) fell by over 6%, with pending details on Hainan's duty-free policies, and institutions noting that the closure operations have a dual impact on offshore duty-free business [7] Group 6: Technology Sector - Qianxun Technology (01640) fell by over 3%, having retreated 23% from its previous high, with recent comments from Yu Weiwen emphasizing the need to avoid excessive speculation on stablecoins [8]

Core Insights - The molded bottle market holds a significant share in the borosilicate glass segment, accounting for approximately 44% of the market in 2024 [1] - The market for borosilicate ampoules is projected to grow from 600 million yuan in 2018 to 2.5 billion yuan in 2024 [2] - The market for neutral borosilicate molded bottles is expected to increase from 900 million yuan in 2018 to 3.8 billion yuan in 2024 [5] - The market for neutral borosilicate tubular bottles (excluding ampoules) is anticipated to grow from 600 million yuan in 2018 to 2.3 billion yuan in 2024 [6] - The strategic positioning of the borosilicate glass market indicates that neutral borosilicate molded bottles and ampoules are "star markets" with high growth potential and strong competitive positions [8] Market Analysis - The molded bottle segment is the largest within the borosilicate glass market, highlighting its importance in the pharmaceutical packaging industry [1] - The growth trajectory of the borosilicate ampoule market reflects increasing demand, with a substantial rise in market size over the years [2] - The neutral borosilicate molded bottle market is also experiencing significant growth, indicating a robust demand for this type of packaging [5] - The neutral borosilicate tubular bottle market, while growing, is currently positioned with moderate demand potential and competition [6] - The analysis using the Boston Matrix framework suggests that the borosilicate glass industry has promising segments that could attract investment and development [8]

Core Viewpoint - As of July 18, 160 stocks reached their 52-week highs, with notable performances from China New Economy Investment (00080), Aoyuan Group Equity (02905), and Zhong An Holdings Group (08462) showing high growth rates of 288.89%, 55.28%, and 50.00% respectively [1][2]. Summary by Category 52-Week High Performers - China New Economy Investment (00080) closed at 0.440, with a peak price of 0.700, achieving a growth rate of 288.89% [2]. - Aoyuan Group Equity (02905) closed at 0.218, with a peak price of 0.250, achieving a growth rate of 55.28% [2]. - Zhong An Holdings Group (08462) closed at 0.221, with a peak price of 0.228, achieving a growth rate of 50.00% [2]. - Other notable performers include Hualian International (00969) with a growth rate of 40.13% and Zhongke Bio (01237) with a growth rate of 37.25% [2]. Additional High Performers - Wanma Holdings (06928) closed at 0.550 with a growth rate of 30.43% [2]. - Lepu Biopharma-B (02157) closed at 7.940 with a growth rate of 24.54% [2]. - Other stocks with significant growth include ZhiJianYueDong (06860) at 17.14% and China Jindian Group (08281) at 17.12% [2]. 52-Week Low Performers - The document also lists stocks that reached their 52-week lows, with XI Ernan CO-U (09311) showing a decline of 16.10% [6]. - Other notable declines include XI Ernan CO (07311) at -12.62% and Haotian International Construction Investment (01341) at -5.70% [6].